Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triple-negative breast cancer
Biotech
BioNTech posts overall survival data on would-be Keytruda killer
BioNTech reported an 18-month overall survival rate of 69.7%, beating the cross-trial benchmark and supporting use in a broader population.
Nick Paul Taylor
Dec 10, 2024 9:00am
Death drives Lyell to take 2-track approach to dose escalation
Jun 26, 2024 10:00am
Gilead draws up $20M pact with cancer biotech Cartography
May 28, 2024 10:26am
Puma pounces on failed Takeda drug, snapping up cancer prospect
Sep 21, 2022 9:05am
CytomX puts lead ADC on the block after phase 2 data underwhelm
Jul 7, 2022 8:45am
An mRNA therapy might boost response to I-O in breast cancer
Mar 22, 2022 9:10am
